DE69716226D1 - Difluoroprostaglandin-Derivate und ihre Anwendung - Google Patents

Difluoroprostaglandin-Derivate und ihre Anwendung

Info

Publication number
DE69716226D1
DE69716226D1 DE69716226T DE69716226T DE69716226D1 DE 69716226 D1 DE69716226 D1 DE 69716226D1 DE 69716226 T DE69716226 T DE 69716226T DE 69716226 T DE69716226 T DE 69716226T DE 69716226 D1 DE69716226 D1 DE 69716226D1
Authority
DE
Germany
Prior art keywords
group
medicine
difluoroprostaglandin
derivatives
difluoroprostaglandin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716226T
Other languages
English (en)
Other versions
DE69716226T2 (de
Inventor
Eiichi Shirasawa
Masaaki Kageyama
Tadashi Nakajima
Takashi Nakano
Nobuaki Mori
Hideshi Sasakura
Yasushi Matsumura
Yoshitomi Morizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69716226(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of DE69716226D1 publication Critical patent/DE69716226D1/de
Application granted granted Critical
Publication of DE69716226T2 publication Critical patent/DE69716226T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
DE69716226T 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung Expired - Lifetime DE69716226T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34861496 1996-12-26
JP7405497 1997-03-26
JP17247797 1997-06-27

Publications (2)

Publication Number Publication Date
DE69716226D1 true DE69716226D1 (de) 2002-11-14
DE69716226T2 DE69716226T2 (de) 2003-06-05

Family

ID=27301396

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122008000050C Active DE122008000050I2 (de) 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung
DE69716226T Expired - Lifetime DE69716226T2 (de) 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE122008000050C Active DE122008000050I2 (de) 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung

Country Status (16)

Country Link
US (2) US5886035A (de)
EP (1) EP0850926B1 (de)
JP (2) JP3480549B2 (de)
KR (1) KR100526282B1 (de)
CN (1) CN1108289C (de)
AT (1) ATE225770T1 (de)
CA (1) CA2225761C (de)
DE (2) DE122008000050I2 (de)
DK (1) DK0850926T3 (de)
ES (1) ES2187719T3 (de)
FR (1) FR11C0020I2 (de)
LU (1) LU91943I2 (de)
NL (1) NL300407I2 (de)
NO (2) NO317060B1 (de)
PT (1) PT850926E (de)
TW (1) TW536534B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
IL134241A (en) 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
WO2002022131A1 (fr) * 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
DE60316574T2 (de) * 2002-08-23 2008-07-03 Santen Pharmaceutical Co., Ltd Stabile augentropfen enthaltend latanoprost als wirkstoff
KR101253941B1 (ko) * 2002-09-09 2013-04-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
EP2247075A1 (de) * 2003-12-08 2010-11-03 QUALCOMM Incorporated Hochgeschwindigkeits-Datenschnittstelle mit verbesserter Verknüpfungssynchronisation
ES2588581T3 (es) * 2004-12-09 2016-11-03 Santen Pharmaceutical Co., Ltd. Producto que contiene prostaglandina con átomo de flúor en su molécula
JP4753178B2 (ja) * 2004-12-24 2011-08-24 参天製薬株式会社 プロスタグランジンＦ２α誘導体含有製品
JP5100025B2 (ja) * 2005-03-31 2012-12-19 旭硝子株式会社 プロスタグランジンＦ２α誘導体を有効成分として含む網膜神経細胞保護剤
KR101396731B1 (ko) * 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
CN101160128B (zh) 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
JP2009500315A (ja) * 2005-06-29 2009-01-08 ファイザー・インク フルオロプロスタグランジンのニトロ誘導体
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
CA2681668C (en) * 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
SG193840A1 (en) * 2008-09-04 2013-10-30 Santen Pharmaceutical Co Ltd HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2a DERIVATIVE AS ACTIVE INGREDIENT
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
BR112013002584A2 (pt) 2010-08-02 2016-06-07 Pharma Patent Holding Inc composição, processo de kit para aperfeiçoamento de cabelo
EP3378480A1 (de) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung des stoffwechselsyndroms
WO2012105674A1 (ja) 2011-02-04 2012-08-09 興和株式会社 緑内障予防又は治療のための薬物療法
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2812314A4 (de) * 2012-02-07 2015-08-19 Reddys Lab Ltd Dr Aminsalze von prostaglandinanaloga
EP2857002A4 (de) 2012-05-30 2015-12-09 Asahi Glass Co Ltd Zusammensetzung für haarwachstum
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
NO2753788T3 (de) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (zh) * 2013-10-11 2016-01-27 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103804195B (zh) * 2014-01-26 2016-06-15 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103819436A (zh) * 2014-02-21 2014-05-28 天泽恩源（天津）医药技术有限公司 (3aR,4R,5R,6aS)-4-((E)-3,3-二氟-4-苯氧基丁-1-烯-1-基)-2-氧代六氢-2H-环戊烷[b]呋喃-5-基苯甲酸酯的一种晶型及相应晶体的制备方法
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
KR20160116402A (ko) 2015-03-30 2016-10-10 연성정밀화학(주) 타플루프로스트의 제조방법
WO2017053638A1 (en) 2015-09-22 2017-03-30 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
CN107226790A (zh) * 2016-03-25 2017-10-03 苏州朗科生物技术有限公司 一种高纯度他氟前列素及其类似化合物的制备方法及中间体化合物
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (zh) * 2017-01-10 2018-07-20 江苏恒瑞医药股份有限公司 一种他氟前列素酸的金属盐化合物结晶形式及其制备方法
CN106986766B (zh) * 2017-05-08 2021-01-12 扬子江药业集团有限公司 他氟前列素的制备方法
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
CN112832150B (zh) * 2021-01-27 2022-06-24 中交第三公路工程局有限公司 一种涵洞通道等立面垂直凿毛装置
CN115385793A (zh) * 2021-01-27 2022-11-25 Ａｇｃ株式会社 他氟前列素的纯化方法
CN116120268A (zh) * 2023-03-06 2023-05-16 南京华威医药科技集团有限公司 一种他氟前列素中间体杂质及其制备方法
CN116425707A (zh) * 2023-03-31 2023-07-14 南京华威医药科技集团有限公司 一种他氟前列素中间体异构体杂质及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
WO1998021181A2 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 15-fluoro prostaglandins as ocular hypotensives

Also Published As

Publication number Publication date
NO317060B1 (no) 2004-08-02
JP3480549B2 (ja) 2003-12-22
KR100526282B1 (ko) 2006-05-17
DK0850926T3 (da) 2003-02-17
NO2009006I2 (no) 2012-03-05
NL300407I1 (nl) 2009-11-02
TW536534B (en) 2003-06-11
LU91943I2 (fr) 2012-04-16
JP2004002462A (ja) 2004-01-08
CA2225761A1 (en) 1998-06-26
CA2225761C (en) 2009-04-21
EP0850926B1 (de) 2002-10-09
NO2009006I1 (no) 2009-03-16
ES2187719T3 (es) 2003-06-16
US5886035A (en) 1999-03-23
CN1108289C (zh) 2003-05-14
DE122008000050I2 (de) 2011-06-16
DE122008000050I1 (de) 2009-01-29
PT850926E (pt) 2003-02-28
EP0850926A2 (de) 1998-07-01
EP0850926A3 (de) 1999-06-16
JPH1171344A (ja) 1999-03-16
ATE225770T1 (de) 2002-10-15
KR19980064718A (ko) 1998-10-07
NO976085L (no) 1998-06-29
CN1187486A (zh) 1998-07-15
JP3994074B2 (ja) 2007-10-17
NL300407I2 (nl) 2010-03-01
FR11C0020I2 (fr) 2012-03-16
DE69716226T2 (de) 2003-06-05
NO976085D0 (no) 1997-12-23
US5985920A (en) 1999-11-16
FR11C0020I1 (de) 2011-07-29

Similar Documents

Publication Publication Date Title
DE69716226D1 (de) Difluoroprostaglandin-Derivate und ihre Anwendung
DE69418243T2 (de) N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
PT918776E (pt) Sintese total de acilfulvenos antitumorais
PE34996A1 (es) Nuevo derivado de pirrocarbazol
DE69222459T2 (de) Thiazolidindionderivate, ihre Herstellung und Anwendung
ATE223411T1 (de) 1-methylcarbapenem-derivate
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
DE69202594T2 (de) Zusammensetzung gegen Katarakt.
ATE71364T1 (de) Fluor enthaltende vitamin-d2-derivate.
DE3782229T2 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: 67940.00.00 67942.00.00 20080507; FIRST REGISTRATION: DAENEMARK 43230 20080430

Spc suppl protection certif: 122008000050

Filing date: 20081016

Expiry date: 20171223

Extension date: 20221222

Effective date: 20110302

R081 Change of applicant/patentee

Owner name: SANTEN PHARMACEUTICAL CO., LTD, 9-19, SHIMOSHI, JP

Free format text: FORMER OWNERS: ASAHI GLASS COMPANY, LTD., TOKIO/TOKYO, JP; SANTEN PHARMACEUTICAL CO., LTD, OSAKA, JP

Spc suppl protection certif: 122008000050

Filing date: 20081016

Expiry date: 20171223

Extension date: 20221222

Owner name: AGC INC., JP

Free format text: FORMER OWNERS: ASAHI GLASS COMPANY, LTD., TOKIO/TOKYO, JP; SANTEN PHARMACEUTICAL CO., LTD, OSAKA, JP

Spc suppl protection certif: 122008000050

Filing date: 20081016

Expiry date: 20171223

Extension date: 20221222

R082 Change of representative

Free format text: "PRODUCT NAME: TAFLUPROST : DAENEMARK 43230 20080430

Spc suppl protection certif: 122008000050

Filing date: 20081016

Expiry date: 20171223

Representative=s name: PERREY, RALF, DIPL.-CHEM.UNIV.DR.RER.NAT., DE

Extension date: 20221222

Free format text: "PRODUCT NAME: TAFLUPROST : DAENEMARK 43230 20080430

Spc suppl protection certif: 1,22008E+11

Filing date: 20081016

Expiry date: 20171223

Representative=s name: PERREY, RALF, DIPL.-CHEM.UNIV.DR.RER.NAT., DE

Extension date: 20221222

Free format text: PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: 67940.00.00 67942.00.00 20080507; FIRST REGISTRATION: DAENEMARK 43230 20080430

Spc suppl protection certif: 122008000050

Filing date: 20081016

Expiry date: 20171223

Representative=s name: PERREY, RALF, DIPL.-CHEM.UNIV.DR.RER.NAT., DE

Extension date: 20221222